Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets

Arrowhead Pharmaceuticals, Inc. ((ARWR)) has held its Q2 earnings call. Read on for the main highlights of the call.

Arrowhead Pharmaceuticals’ latest earnings call struck an upbeat yet measured tone, as management highlighted a fast start for newly launched REDEMPLO, strong triglyceride‑lowering data for plozasiran, and a fortified balance sheet that extends the company’s runway. Investors were reminded, however, that product revenue is still nascent, losses are widening, and key late‑stage readouts in 2026 will heavily influence the company’s commercial trajectory.

Surging REDEMPLO Launch Momentum

REDEMPLO, approved by the U.S. FDA in November 2025 for familial chylomicronemia syndrome, is off to a stronger‑than‑expected debut with more than 400 prescriptions written to date and roughly 30 new scripts per week. Management noted prescriptions nearly tripled over the fiscal quarter and climbed more than 40% in the most recent four‑week period, with about 85% of patients APOC3‑naive and over 10% switching from a rival therapy.

Plozasiran Shows Compelling Long‑Term Efficacy

Two‑year open‑label extension data for plozasiran in severe and high triglyceride populations showed sustained and deep lipid reductions, reinforcing its clinical profile ahead of Phase III readouts. Median triglyceride cuts reached 83% in severe hypertriglyceridemia and 67% in high triglycerides, with most patients achieving levels below 150 mg/dL and no adjudicated acute pancreatitis events reported over the two‑year period.

Multiple Near‑Term Clinical Catalysts Lined Up

Arrowhead emphasized a dense slate of upcoming data releases in the second half of 2026 that could materially reshape its value proposition. Top‑line Phase III results from SHASTA‑3 and SHASTA‑4 for plozasiran, along with the first clinical data from dual‑siRNA candidate ARO‑DIMER‑PA and initial CNS platform data from ARO‑MAPT, are all expected around the third quarter, with further updates for ARO‑INHBE and ARO‑ALK7 across the back half of the year.

Broad and Innovative RNAi Pipeline

The company now counts more than 20 clinical programs spanning liver, muscle, adipose tissue, central nervous system and lung, underscoring its ambition to be a diversified RNAi platform player. Notable among these is ARO‑DIMER‑PA, billed as the first dual‑functional siRNA in human testing, and ARO‑MAPT, a subcutaneously delivered CNS candidate designed to cross the blood‑brain barrier and potentially anchor a new neurodegeneration franchise.

Advancing Global Regulatory Footprint

Beyond the U.S. launch, REDEMPLO has secured approvals in Australia, China and Canada, and received a positive opinion from the European regulator’s scientific committee supporting EU authorization. Management signaled plans for launches later in 2026 in Canada and select European markets including the U.K., while commercialization in Greater China will be handled by partner Sanofi to broaden regional reach.

Reinforced Balance Sheet and Capital Flexibility

Arrowhead significantly strengthened its financial position by completing its largest capital raise to date, issuing $700 million of zero‑coupon convertible senior notes alongside a $230 million common stock offering, both described as heavily oversubscribed. As of March 31, 2026, the company reported nearly $1.8 billion in cash and investments, having generated over $1 billion during the quarter from financings and partner payments, providing ample runway for its expansive development plans.

Strategic Business Development Adds Optionality

A new exclusive license agreement with Madrigal for ARO‑PNPLA3 showcased Arrowhead’s willingness to monetize non‑core assets while maintaining exposure to upside through milestones and royalties. The deal includes $25 million upfront with the potential for up to $975 million in future payments, and complements ongoing collaborations with Sarepta and Novartis, which continue to contribute to recognized revenue.

Encouraging Early Commercial and Payer Dynamics

To simplify pricing across indications, Arrowhead reset REDEMPLO’s wholesale acquisition cost to $45,000 per year, and early payer interactions have been described as broadly supportive of patient access. The company noted emerging coverage policies that accept both genetic and clinical diagnostic approaches for FCS, aiming to reduce barriers to treatment and accelerate adoption in the roughly 6,500‑patient U.S. market.

Revenue Base Still Narrow and Product Sales Modest

Despite the strong narrative around launch momentum, REDEMPLO’s first full quarter on the market translated into only around $1 million of estimated net product sales, highlighting how early the commercial ramp remains. Total quarterly revenue of $74 million was driven predominantly by collaboration and license income, underscoring Arrowhead’s current reliance on partners rather than organic product sales for its top line.

Net Loss Widens on Higher Operating Spend

The company reported a net loss of $132.7 million, or $0.93 per share, for the quarter, a sharp swing from the prior‑year period that benefited from more than $540 million in one‑time Sarepta revenue. Operating expenses climbed to roughly $215 million, up about a third year over year, as research and development spending increased by $40 million and selling, general and administrative costs rose $13 million to support the growing pipeline and commercial infrastructure.

Clinical and Competitive Risks Remain Material

Management acknowledged that critical registrational trials, including pooled SHASTA pancreatitis analyses and early studies of ARO‑DIMER‑PA and ARO‑MAPT, remain blinded or at an early stage, leaving outcomes uncertain and potentially affecting future development plans such as SHASTA‑5 enrollment. At the same time, lowering REDEMPLO’s list price to $45,000 still leaves it above a competing product at $40,000, raising the prospect of reimbursement pressure even as Arrowhead argues for a superior clinical profile.

Pipeline Uncertainty and Limited Commercial Transparency

Some investor skepticism persists around metabolic programs like INHBE, particularly after prior data, and Arrowhead now frames INHBE and ALK7 as combination candidates with GLP‑1 agents, which could complicate interpretation and pathway to market. The company also declined to provide detailed gross‑to‑net guidance or granular unit sales metrics, limiting near‑term visibility into REDEMPLO’s true pricing dynamics and realized economics.

Guidance Highlights and 2026–2027 Outlook

Looking ahead, Arrowhead reiterated that pooled SHASTA‑3 and SHASTA‑4 data, along with MUIR‑3, should arrive in the third quarter of 2026, supporting a supplemental U.S. filing before year‑end and a potential new approval in the second half of 2027, while long‑term plozasiran data continue to support its safety and efficacy. Additional milestones include first readouts for ARO‑DIMER‑PA and ARO‑MAPT late in 2026, updates on INHBE and ALK7, YOSEMITE enrollment completion with potential filings by 2027, and disciplined use of the company’s roughly $1.8 billion in cash to balance pipeline expansion with ongoing operating losses.

Arrowhead’s earnings call painted a picture of a company in transition from a partnership‑driven RNAi innovator to an emerging commercial player, buoyed by early REDEMPLO traction and a deep bench of clinical assets. For investors, the near term will hinge on execution in FCS, careful management of rising expenses, and the outcome of pivotal 2026 readouts that could either validate the platform and justify the elevated spend or force a reassessment of the current growth strategy.